ACSL4 and colorectal carcinoma: As were shown in Figure 2G–I, low expression of GPX4 (p < 0.001; 95% CI: 0.54–0.84; HR:0.68), high expression of NOX1 (p < 0.001, 95% CI: 1.20–1.85; HR:1.49), and high expression of FACL4 (p < 0.001, 95% CI: 1.12–1.75; HR:1.47) demonstrated better prognosis in patients with CRC.